399 related articles for article (PubMed ID: 31591468)
41. Waldenström macroglobulinemia.
Treon SP; Hunter ZR; Castillo JJ; Merlini G
Hematol Oncol Clin North Am; 2014 Oct; 28(5):945-70. PubMed ID: 25212891
[TBL] [Abstract][Full Text] [Related]
42. Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Castillo JJ; Buske C; Trotman J; Sarosiek S; Treon SP
Am J Hematol; 2023 Feb; 98(2):338-347. PubMed ID: 36415104
[TBL] [Abstract][Full Text] [Related]
43. Managing complications secondary to Waldenström's macroglobulinemia.
Pessach I; Dimopoulos MA; Kastritis E
Expert Rev Hematol; 2021 Jul; 14(7):621-632. PubMed ID: 34170207
[No Abstract] [Full Text] [Related]
44. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP
Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557
[TBL] [Abstract][Full Text] [Related]
45. Ibrutinib in the management of Waldenstrom macroglobulinemia.
Yosef A; Touloukian EZ; Nambudiri VE
J Oncol Pharm Pract; 2019 Mar; 25(2):434-441. PubMed ID: 29996737
[TBL] [Abstract][Full Text] [Related]
46. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Yang G; Buhrlage SJ; Tan L; Liu X; Chen J; Xu L; Tsakmaklis N; Chen JG; Patterson CJ; Brown JR; Castillo JJ; Zhang W; Zhang X; Liu S; Cohen P; Hunter ZR; Gray N; Treon SP
Blood; 2016 Jun; 127(25):3237-52. PubMed ID: 27143257
[TBL] [Abstract][Full Text] [Related]
47. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D; Tam CS; Joshua D; Ho JP; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Horvath N; Lee C; Zannettino A; Brown R; Augustson B; Jaksic W; Gibson J; Kalff A; Johnston A; Trotman J; Kalro A; Grigoriadis G; Ward C; Prince HM
Intern Med J; 2017 Jan; 47(1):35-49. PubMed ID: 28076910
[TBL] [Abstract][Full Text] [Related]
48. Current and Emerging Treatments for Waldenström Macroglobulinemia.
Grimont CN; Castillo Almeida NE; Gertz MA
Acta Haematol; 2021; 144(2):146-157. PubMed ID: 32810857
[TBL] [Abstract][Full Text] [Related]
49. Novel treatment options for Waldenström macroglobulinemia.
Leblebjian H; Agarwal A; Ghobrial I
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S310-6. PubMed ID: 24290218
[TBL] [Abstract][Full Text] [Related]
50. Toward personalized treatment in Waldenström macroglobulinemia.
Castillo JJ; Treon SP
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):365-370. PubMed ID: 29222280
[TBL] [Abstract][Full Text] [Related]
51. Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage.
Sarosiek S; Castillo JJ
Drugs; 2024 Jan; 84(1):17-25. PubMed ID: 38055179
[TBL] [Abstract][Full Text] [Related]
52. Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.
Ghafoor B; Masthan SS; Hameed M; Akhtar HH; Khalid A; Ghafoor S; Allah HM; Arshad MM; Iqbal I; Iftikhar A; Husnain M; Anwer F
Ann Hematol; 2024 Jun; 103(6):1859-1876. PubMed ID: 37414960
[TBL] [Abstract][Full Text] [Related]
53. The Management of Relapsed or Refractory Waldenström's Macroglobulinemia.
García-Sanz R; Tedeschi A
Hematol Oncol Clin North Am; 2023 Aug; 37(4):727-749. PubMed ID: 37246089
[TBL] [Abstract][Full Text] [Related]
54. Waldenstrom's macroglobulinemia in the era of immunotherapy.
Vaxman I; Gertz M
Leuk Lymphoma; 2020 Jun; 61(6):1292-1304. PubMed ID: 31960730
[TBL] [Abstract][Full Text] [Related]
55. Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement.
Ferrero S; Gentile M; Laurenti L; Mauro FR; Martelli M; Sportoletti P; Visco C; Zinzani PL; Tedeschi A; Varettoni M
Hematol Oncol; 2022 Aug; 40(3):332-340. PubMed ID: 35212014
[TBL] [Abstract][Full Text] [Related]
56. Waldenstrom macroglobulinemia.
Leleu X; Roccaro AM; Moreau AS; Dupire S; Robu D; Gay J; Hatjiharissi E; Burwik N; Ghobrial IM
Cancer Lett; 2008 Oct; 270(1):95-107. PubMed ID: 18555588
[TBL] [Abstract][Full Text] [Related]
57. Waldenström macroglobulinemia: from biology to treatment.
Sahin I; Leblebjian H; Treon SP; Ghobrial IM
Expert Rev Hematol; 2014 Feb; 7(1):157-68. PubMed ID: 24405328
[TBL] [Abstract][Full Text] [Related]
58. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; Sanz RG; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyz J; Fernández de Larrea C; Belada D; Libby E; Matous JV; Motta M; Siddiqi T; Tani M; Trneny M; Minnema MC; Buske C; Leblond V; Trotman J; Chan WY; Schneider J; Ro S; Cohen A; Huang J; Dimopoulos M
Blood; 2020 Oct; 136(18):2038-2050. PubMed ID: 32731259
[TBL] [Abstract][Full Text] [Related]
59. Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.
Deshpande A; Munoz J
Ther Clin Risk Manag; 2022; 18():657-668. PubMed ID: 35770040
[TBL] [Abstract][Full Text] [Related]
60. Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review.
Moore DC
J Oncol Pharm Pract; 2021 Dec; 27(8):1993-1999. PubMed ID: 34558376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
